Biosimilars

At Medniqa, we believe quality healthcare is a fundamental right, not a privilege. We’re dedicated to ensuring that even the most remote communities have access to life-saving pharmaceutical products. We exist to turn pharmaceutical potential into patient impact.

Corporate Identity Number: U51391GJ2022PTC131260

Biosimilars

Bevacizumab

Cetrorelix Acetate

Lanreotide Acetate

Liposomal Amphotericin B

Liposomal Doxorubicin

Liraglutide

NAB Paclitaxel

Octreotide Acetate

Peg- Filgrastim

Semaglutide Injection

Trastuzumab

Trastuzumab

Triptorelin Acetate

Solutions

Services

Resources:

Partner with Us: